The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.

Autor: Çömez A; Department of Ophthalmology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey. draysegulcomez@gmail.com., Karaküçük Y; Department of Ophthalmology, Faculty of Medicine, Sutcu Imam University, Kahramanmaras, Turkey.; Department of Ophthalmology, Faculty of Medicine, Selcuk University, Konya, Turkey., Özmen MC; Department of Ophthalmology, Gazi University School of Medicine, Ankara, Turkey., Çelemler P; Department of Ophthalmology, Gaziantep Children's Hospital, Gaziantep, Turkey., Saygılı O; Department of Ophthalmology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
Jazyk: angličtina
Zdroj: Eye (London, England) [Eye (Lond)] 2021 Dec; Vol. 35 (12), pp. 3302-3310. Date of Electronic Publication: 2021 Jan 29.
DOI: 10.1038/s41433-021-01413-4
Abstrakt: Objectives: This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences.
Methods: This retrospective cohort study reviewed the records of infants with ROP (Type 1 and APROP), who received IVB treatment between March 2013 and February 2018.
Results: A total of 257 eyes from 130 cases (unilateral eyes in three cases) were included. Cases were followed for 121.7 ± 45.7 weeks (range: 70-260 weeks). Recurrence requiring treatment was determined in 14.8% of all eyes at a mean of 9.6 ± 2.7 weeks (range: 6-15 weeks) after initial treatment and a mean of 42.3 ± 2.2 weeks (range: 38-48 weeks) postmenstrual age. Recurrence requiring treatment was observed in 20.8% of APROP and 5.8% of Type 1 ROP eyes at a statistically significant difference (p = 0.001). Persistent avascular areas were found in 54 eyes (25.8%) at the corrected age of 1 year, and prophylactic laser treatment was applied. This was statistically significantly higher in APROP (38.6%) than in Type 1 ROP (10.5%) (p < 0.001). An unfavourable structural outcome (progression to retinal detachment) occurred in one eye (0.4%), which developed insufficient regression and progression.
Conclusions: IVB monotherapy is effective for APROP and Type 1 ROP with Zone 1 and posterior Zone 2 localisation. However, because of recurrences requiring treatment and persistent peripheral avascular areas, severe, late complications must be considered, and follow-up examinations must be made. Prophylactic laser treatment for persistent avascular areas seems effective for minimising long-term complications.
(© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.)
Databáze: MEDLINE
Externí odkaz: